OH2

OH2 is a genetically engineered oncolytic herpes simplex virus type 2 (HSV‑2) designed to selectively replicate in tumor cells and express human granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance antitumor immune responses. The virus is derived from the wild-type HSV‑2 strain HG52, with deletions of the ICP34.5 neurovirulence gene for safety and tumor selectivity, and the ICP47 gene to improve antigen presentation. Preclinical studies have shown potent oncolytic activity, immunogenicity, and safety. Clinically, it has been evaluated as a single agent or in combination with anti-PD‑1 antibody HX008 in patients with advanced solid tumors[4][2]. It is being developed primarily for malignant melanoma (Phase III), bladder cancer and colorectal cancer (Phase II), as well as other solid tumors.

Brand names

OH2 injectionOH-2 injectionOH 2 injectionOH2 Oncolytic Viral TherapyOH-2 Oncolytic Viral TherapyOH 2 Oncolytic Viral Therapy

Other names

Oncolytic type 2 Herpes Simplex virus